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Effects of insulin on immunoreactive protein kinase C were examined in BC3H-I myocytes. Insulin provoked rapid dose- 
dependent decreases in cytosolic enzyme. and transient increases and subsequent decreases in membrane-associated en- 
zyme. Phorbol esters provoked similar changes. Our findings suggest that insulin provokes the translocative activation 
of protein kinase C. 
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1. INTRODUCTION 
Insulin increases PKC enzyme activity in mem- 
brane fractions of BC3H-I myocytes [l] and rat 
diaphragm [2], but does not decrease cytosolic en- 
zyme activity. This activation pattern differs from 
that of phorbol esters [3], which decrease cytosolic 
and transiently increase membrane PKC activity. 
The latter indicates that PKC translocates from 
cytosol to membrane, and undergoes subsequent 
proteolytic degradation [4], thus leading to 
decreases in PKC content, particularly in the 
cytosol. Because insulin did not diminish cytosolic 
PKC enzymatic activity in the above and other 
[5,6] tissues, it has been questioned whether insulin 
truly activates PKC. However, insulin provokes 
large increases in DAG, which may increase 
cytosolic enzyme activity and mask decreases in en- 
zyme content. Thus, simple measurement of en- 
zyme activity may not reveal changes in content, 
subcellular distribution and translocation of PKC. 
To evaluate the latter, we measured immunoreac- 
tive PKC. 
2. EXPERIMENTAL 
Correspondence address: R.V. Farese, Research Service (VAR 
151), J.A. Haley Veterans’ Hospital, 13000 Bruce Downs Blvd., 
Tampa, FL 33612, USA 
PKC was purified from rat (Holtzman) brains, which were 
homogenized in cold 0.25 M sucrose buffer containing 20 mM 
Tris (pH 7.5), 50 mM 2-mercaptoethanol, 0.2% Triton X-100, 
10 mM EGTA, 2 mM EDTA, 0.4 mM leupeptin and 2 mM 
PMSF and centrifuged at 100000 X g for 1 h. The supernatant 
was applied to a DEAE-cellulose column equilibrated with buf- 
fer A [20 mM Tris-HCI (pH 7.5), 50 mM 2-mercaptoethanol, 
10 mM EGTA, 2 mM EDTA, 2 mM PMSF]. The column was 
washed and eluted with a linear gradient of O-O.4 M NaCl in 
buffer A. Fractions containing PKC enzyme activity (see [l]) 
were pooled, adjusted to 1.5 M NaCl and loaded on a phenyl- 
Sepharose CL-4B column equilibrated with buffer B [1.5 M 
NaCI, 20 mM Tris-HCI (pH 7.5), 0.5 mM EGTA, 0.5 mM ED- 
TA, 50 mM 2-mercaptoethanol, 2 mM PMSF]. The column 
was washed and eluted with a linear gradient of 1.5-O M NaCl 
in buffer B. Fractions containing PKC were pooled and applied 
to a preparative SDS-PAGE slab gel. PKC was located as an 
80 kDa protein by PS/Ca*+-dependent autophosphorylation 
and used to immunize New Zealand rabbits, as described by 
Vaitukaitis et al. [7]. 
Abbreviations: PKC, protein kinase C; DAG, diacylglycerol; Procedures for culturing and subcellular fractionation of 
TPA, 12-0-tetradecanoyl phorbol-13-acetate; SDS-PAGE, BC3H-I myocytes have been described [l]. Cells were grown in 
SDS-polyacrylamide gel electrophoresis; PMSF, phenylmethyl- Dulbecco’s modified Eagle’s medium supplemented with 15% 
sulfonyl fluoride; DMSO, dimethyl sulfoxide process serum replacement-l (Sigma), and fed 25 mM glucose 
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24 h before experimentation. Cells were washed three times 
with Dulbecco’s phosphate-buffered saline (DPBS) containing 
0.1 mM CaClz and 1 mg/ml glucose, and preincubated for 
20 min at 37°C. Insulin (Elanco), TPA (Sigma), or vehicle (con- 
trols) was added, and after l-20 min reactions were terminated 
by washing the cells twice with ice-cold DPBS. Cells were gently 
scraped, sonicated in buffer C [IO mM Tris-HCl (pH 7.9, 
10 mM EGTA, 25 mM MgClz, 0.25 M sucrose, 2 mM PMSF, 
0.4 mM leupeptin], and centrifuged at 100000 x g for 30 min 
to obtain cytosol and membrane fractions. The latter was 
resuspended in buffer C with 1 Vo Triton X-100 and centrifuged 
to obtain the solubilized membrane fraction. 
Cytosol and solubilized membrane fractions (50 pg protein) 
were subjected to SDS-PAGE (8% gel) and proteins were elec- 
trophoretically transferred to nitro-.ellulose 18). Nonspecific 
binding sites were blocked with 3% geiatin in 20 mM Tris-HCl 
(pH 7.5) containing 500 mM NaCl (TBS). The nitrocellulose 
sheets were washed with TBS containing 0.05% Tween 20 
(TTBS), incubated for 2 h with PKC antiserum in 1% gelatin 
in TTBS, washed and incubated for 1 h with goat anti-rabbit 
antibody coupled to horseradish peroxidase in 1% gelatin- 
TTBS. Immunoreactive proteins were visualized with 
4-chloro-1-naphthol and HzOz, and quantified with a laser den- 
sitometric scanner (LKB). Hydroxyapatite-purified, 80 kDa rat 
brain protein kinase C was used as a molecular mass standard. 
3. RESULTS 
Our polyclonal antiserum detected a major 
80 kDa immunoreactive protein in crude cytosol 
and membrane fractions of BC3H-1 myocytes (figs 
1,2). Identical results were obtained after purifica- 
tion of PKC by Mono Q column chromatography, 
followed by resolution of type I-III isozymes by 
hydroxyapatite column chromatography [9], or 
when we used an antiserum (provided by Drs 
Bryan Roth and John Mehegan), which was raised 
to a synthetic type II peptide sequence and 
specifically recognizes type II PKC (not shown). 
Temporal effects of 100 nM insulin on im- 
munoreactive PKC are depicted in fig.1 by 
representative immunoblots and densitometric 
scans. Results of scans of control and insulin- 
treated samples from several experiments were 
pooled, and cytosolic immunoreactive PKC 
decreased 8 f 4% (mean + SE, n = 3) at 1 min, 53 
f 10% (n = 5) at 10 min, and 77 f % (n = 4) at 
20 min of insulin treatment. Immunoreactive PKC 
in membrane fractions increased 35 + 20% (n = 3) 
at 1 min, and then decreased 45 f 6% (n = 3) at 
10 min, and 65 + 9% (n = 6) at 20 min of insulin 
treatment. 
As shown in fig.2, increasing concentrations of 
insulin provoked graded decreases in cytosolic 
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Fig.1. Western blots (left) and densitometric scans (right) of 
protein kinase C in cytosol (A$) and membrane (B,D) 
fractions of BC3H-1 myocytes. Cells were treated with 100 nM 
insulin for 1, 10, or 20 min. or with buffer alone (controls) for 
20 min. 
PKC immunoreactivity over a 20 min treatment 
period. Increases in membrane PKC immunoreac- 
tivity were observed with 1 nM insulin, but higher 
concentrations provoked decreases. 
TPA (2 PM) provoked decreases in cytosolic and 
membrane-bound immunoreactive PKC, which 
were similar to, although slightly less pronounced 
than, those provoked by insulin (fig.3). 
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Fig.2. Dose-related effects of insulin (over 20 min) on 
immunoreactive protein kinase C in cytosol and membrane 
fractions of BC3H-1 myocytes. 
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Fig.3. Western blot analysis of TPA effects on protein kinase 
C in cytosol (A) and membrane (B) fractions of BC3H-1 
myocytes. Cells were treated for 10 or 20 min with 2 pM TPA 
in DMSO, or DMSO alone. 
4. DISCUSSION 
Although not apparent in studies of insulin ef- 
fects on enzymatic activity of PKC [1,2,5,6], in- 
sulin provoked rapid decreases in cytosolic, and 
transient increases and subsequent decreases in 
membrane-associated immunoreactive PKC. 
These findings suggest that ranslocation and 
subsequent degradation of PKC occur during in- 
sulin treatment, and indicate that the enzyme has 
been activated in vivo. In keeping with this 
hypothesis, similar changes in cytosolic and 
membrane-associated immunoreactive PKC were 
observed with TPA, a known activator of the en- 
zyme [l]. 
The observed changes in immunoreactive PKC 
duping insulin and TPA treatment presumably 
reflect changes in enzyme content. It may therefore 
seem paradoxical that insulin-induced decreases in 
apparent content of cytosolic PKC were not 
paralleled by observed decreases in enzymatic ac- 
tivity [ 11. However, enzyme activity was previously 
assayed with crude cytosol, and insulin-induced in- 
creases in DAG may increase the I’,,,,, of PKC, 
even in the cytosol fraction. Thus, a decrease in en- 
zyme content may be offset by an increase in en- 
zymatic activity. Indeed, if the cytosolic PKC is 
purified by Mono Q column chromatography to 
remove sufficient endogenous DAG, and then 
assayed with optimal concentrations of diolein, 
control cytosolic PKC activity is 2-fold greater 
than that measured in insulin-treated cytosol (un- 
published): these results, like those of the present 
study, indicate that cytosolic PKC content is 
decreased by insulin treatment. Along these lines, 
whether the endogenous DAG which activates 
cytosolic PKC in in vitro assays of crude cytosol is 
present in this fraction in vivo, or is an artifact of 
homogenization, is presently uncertain. Never- 
theless, insulin probably activates PKC both by 
DAG-induced activation, as well as by transloca- 
tion of the enzyme to the membrane fraction. 
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